In conclusion, we have developed a semi-automated, objective, and reproducible immunofluorescence method optimized for assessing dystrophin levels in muscle biopsies from BMD or DMD patients in natural history studies or clinical studies with compounds aiming to restore dystrophin expression. This evidence concerns the gene DMD and Duchenne muscular dystrophy.